Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
CELGENE CORPORATION v. HETERO LABS LIMITED et al
Case Number:
2:17-cv-03387
Court:
Nature of Suit:
Judge:
Firms
- Carella Byrne
- FisherBroyles
- Flaster Greenberg
- Fleming Ruvoldt
- Hill Wallack
- Kirkland & Ellis
- Nukk Freeman
- Quinn Emanuel
- Rivkin Radler
- Saiber LLC
- Saul Ewing
- Walsh Pizzi
Companies
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Breckenridge Pharmaceutical Inc.
- Celgene Corp.
- Hetero Drugs Ltd.
- Mylan NV
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
-
August 20, 2021
Bristol-Myers Unit Settles Over Generic Cancer Drug
Bristol-Myers unit Celgene has reached a settlement with India-based Hetero Labs, marking the final settlement to come out of Celgene's 2017 lawsuit against a raft of generic-drug makers over patents for its blockbuster cancer medication Pomalyst, according to a consent judgment approved Thursday in New Jersey federal court.
-
March 02, 2018
Mylan Can't Escape Celgene's Suit Over Skin Cancer Patent
A New Jersey federal judge on Friday refused to dismiss Mylan NV from a suit Celgene Corp. brought against the pharmaceutical company and others to block generic versions of its skin cancer treatment, giving Celgene time to investigate whether Mylan has an established business in the Garden State.